Seminars in Hematology
Volume 45, Issue 1 , Pages 60-70 , January 2008

Myelodysplastic Syndrome in Children and Adolescents

  • Charlotte M. Niemeyer

      Affiliations

    • Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Freiburg, Freiburg, Germany.
    • Corresponding Author InformationAddress correspondence to Charlotte M. Niemeyer, MD, Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Freiburg, Freiburg i.Br., Germany.
    • ,
  • Irith Baumann

      Affiliations

    • Institute of Pathology, Clinical Center Bayreuth, Bayreuth, Germany.

References 

  1. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277–282
  2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  3. Jaffe ES. World Health Organization Classification of Tumours (Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues). Lyon, France: IARC Press; 2001;
  4. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: A population-based study of incidence and survival. Br J Haematol. 2003;121:758–767
  5. Stary J, Baumann I, Creutzig U, Harbott J, Michalova K, Niemeyer C. Getting the numbers straight in pediatric MDS: Distribution of subtypes after exclusion of down syndrome. Pediatr Blood Cancer. 2007;Apr 23 [Epub ahead of print]
  6. Mandel K, Dror Y, Poon A, Freedman MH. A practical, comprehensive classification for pediatric myelodysplastic syndromes: The CCC system. J Pediatr Hematol Oncol. 2002;24:596–605
  7. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: Incidence and predisposing conditions. Leukemia. 1995;9:1569–1572
  8. Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 1999;106:1027–1032
  9. Sasaki H, Manabe A, Kojima S, Tsuchida M, Hayashi Y, Ikuta K, et al. Myelodysplastic syndrome in childhood: A retrospective study of 189 patients in Japan. Leukemia. 2001;15:1713–1720
  10. Luna-Fineman S, Shannon KM, Atwater SK, Davis J, Masterson M, Ortega J, et al. Myelodysplastic and myeloproliferative disorders of childhood: A study of 167 patients. Blood. 1999;93:459–466
  11. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: The complexity of stem-cell diseases. Nat Rev Cancer. 2007;7:118–129
  12. Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell. 2004;6:547–552
  13. Klein C, Grudzien M, Appaswamy G, Germeshausen M, Sandrock I, Schaffer AA, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet. 2007;39:86–92
  14. Dale DC, Person RE, Bolyard AA, Aprikyan AG, Bos C, Bonilla MA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood. 2000;96:2317–2322
  15. Person RE, Li FQ, Duan Z, Benson KF, Wechsler J, Papadaki HA, et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet. 2003;34:308–312
  16. Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet. 2003;33:97–101
  17. Flygare J, Karlsson S. Diamond-Blackfan anemia: Erythropoiesis lost in translation. Blood. 2007;109:3152–3154
  18. Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat. 2007;28:1178–1182
  19. Vulliamy T, Dokal I. Dyskeratosis congenita. Semin Hematol. 2006;43:157–166
  20. Walne AJ, Vulliamy T, Marrone A, Beswick R, Kirwan M, Masunari Y, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet. 2007;16:1619–1629
  21. Ortmann CA, Niemeyer CM, Wawer A, Ebell W, Baumann I, Kratz CP. TERC mutations in children with refractory cytopenia. Haematologica. 2006;91:707–708
  22. Yamaguchi H, Baerlocher GM, Lansdorp PM, Chanock SJ, Nunez O, Sloand E, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood. 2003;102:916–918
  23. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166–175
  24. Calado RT, Graf SA, Wilkerson KL, Kajigaya S, Ancliff PJ, Dror Y, et al. Mutations in the SBDS gene in acquired aplastic anemia. Blood. 2007;110:1141–1146
  25. Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333:487–493
  26. Le Beau MM, Espinosa R, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996;88:1930–1935
  27. Curtiss NP, Bonifas JM, Lauchle JO, Balkman JD, Kratz CP. Emerling bone marrow, et al: Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics. 2005;85:600–607
  28. Sloand EM, Pfannes L, Chen G, Shah S, Solomou EE, Barrett J, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood. 2007;109:2399–2405
  29. Taki T, Sako M, Tsuchida M, Hayashi Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood. 1997;89:3945–3950
  30. Ahuja HG, Felix CA, Aplan PD. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood. 1999;94:3258–3261
  31. Jekic B, Novakovic I, Lukovic L, Kuzmanovic M, Popovic B, Pastar I, et al. Low frequency of NRAS and KRAS2 gene mutations in childhood myelodysplastic syndromes. Cancer Genet Cytogenet. 2004;154:180–182
  32. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 2006;108:2041–2044
  33. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2006;20:1943–1949
  34. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood. 2003;102:43–52
  35. Kardos G, Baumann I, Passmore SJ, Locatelli F, Hasle H, Schultz KR, et al. Refractory anemia in childhood: A retrospective analysis of 67 patients with particular reference to monosomy 7. Blood. 2003;102:1997–2003
  36. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004;118–145
  37. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 2003;362:1628–1630
  38. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?. Semin Hematol. 2000;37:15–29
  39. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100:786–790
  40. Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy (Italian Aplastic Anaemia Study Group). Lancet. 2001;357:43–44
  41. Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol. 2001;115:1015–1022
  42. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902
  43. Mantadakis E, Shannon KM, Singer DA, Finklestein J, Chan KW, Hilden JM, et al. Transient monosomy 7: A case series in children and review of the literature. Cancer. 1999;85:2655–2661
  44. Yusuf U, Frangoul HA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: The Seattle experience. Bone Marrow Transplant. 2004;33:805–814
  45. Locatelli F, Nöllke P, Fischer A. Hematopoietic stem cell transplantation after a myeloablative conditioning regimen in children with refractory cytopenia: Results of a retrospective analysis from the EWOG-MDS group. Leuk Res. 2007;31:S39–S39, (abstr)
  46. Strahm B, Locatelli F, Bader P, Ehlert K, Kremens B, Zintl F, et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant. 2007;40:329–333
  47. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia. 2004;18:460–465
  48. Yoshimi A, Baumann I, Fuhrer M, Bergstrasser E, Gobel U, Sykora KW, et al. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia. Haematologica. 2007;92:397–400
  49. Chan GC, Wang WC, Raimondi SC, Behm FG, Krance RA, Chen G, et al. Myelodysplastic syndrome in children: Differentiation from acute myeloid leukemia with a low blast count. Leukemia. 1997;11:206–211
  50. Hasle H, Arico M, Basso G, Biondi A, Cantù-Rajnoldi A, Creutzig U, et al. Myelodysplastic syndrome and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia. 1999;13:376–385
  51. Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: A report from the Children’s Cancer Group. J Clin Oncol. 2002;20:434–440
  52. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial (The Medical Research Council Adult and Children’s Leukaemia Working Parties). Blood. 1998;92:2322–2333
  53. Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: An international retrospective study. Blood. 2007;109:4641–4647
  54. Hasle H, Baumann I, Bergstrasser E, Fenu S, Fischer A, Kardos G, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia. 2004;18:2008–2014
  55. Webb DK, Passmore SJ, Hann IM, Harrison G, Wheatley K, Chessells JM. Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99. Br J Haematol. 2002;117:33–39
  56. Zecca M, Nollke P, Fischer A. Hematopoietic stem cell transplantation for advanced primary MDS in children: Results of a retrospective analysis from the EWOG-MDS group. Leuk Res. 2007;31:S38–S39(abstr)
  57. Hasle H, Kerndrup G, Yssing M, Clausen N, Ostergaard E, Jacobsen N, et al. Intensive chemotherapy in childhood myelodysplastic syndrome (A comparison with results in acute myeloid leukemia). Leukemia. 1996;10:1269–1273
  58. Stary J, Locatelli F, Niemeyer CM. Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant. 2005;35(suppl 1):S13–S16
  59. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201–1207
  60. Lang P, Greil J, Bader P, Handgretinger R, Klingebiel T, Schumm M, et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis. 2004;33:281–287
  61. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 2002;12:605–611
  62. Davies SM. Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol. 2001;36:536–540
  63. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol. 2001;36:525–535
  64. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2002;99:1909–1912
  65. Leahey AM, Friedman DL, Bunin NJ. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplant. 1999;23:21–25
  66. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249–1256
  67. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: An International Fanconi Anemia Registry study. Blood. 1994;84:1650–1655
  68. Alter BP, Caruso JP, Drachtman RA, Uchida T, Velagaleti GV, Elghetany MT. Fanconi anemia: Myelodysplasia as a predictor of outcome. Cancer Genet Cytogenet. 2000;117:125–131
  69. Tonnies H, Huber S, Kuhl JS, Gerlach A, Ebell W, Neitzel H. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: Gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood. 2003;101:3872–3874
  70. Farzin A, Davies SM, Smith FO, Filipovich A, Hansen M, Auerbach AD, et al. Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: An update of the Cincinnati Children’s experience. Br J Haematol. 2007;136:633–640
  71. Wagner JE, Eapen M, MacMillan ML, Harris RE, Pasquini R, Boulad F, et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood. 2007;109:2256–2262
  72. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006;107:4628–4635
  73. Donadieu J, Leblanc T, Bader MB, Barkaoui M, Fenneteau O, Bertrand Y, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia (Experience of the French Severe Chronic Neutropenia Study Group). Haematologica. 2005;90:45–53
  74. Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood. 2007;110:1648–1655
  75. Zeidler C, Welte K, Barak Y, Barriga F, Bolyard AA, Boxer L, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood. 2000;95:1195–1198
  76. Ginzberg H, Shin J, Ellis L, Morrison J, Ip W, Dror Y, et al. Shwachman syndrome: Phenotypic manifestations of sibling sets and isolated cases in a large patient cohort are similar. J Pediatr. 1999;135:81–88
  77. Dror Y, Durie P, Ginzberg H, Herman R, Banerjee A, Champagne M, et al. Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: A prospective 5-year follow-up study. Exp Hematol. 2002;30:659–669
  78. Lipton JM, Federman N, Khabbaze Y, Schwartz CL, Hilliard LM, Clark JI, et al. Osteogenic sarcoma associated with Diamond-Blackfan anemia: A report from the Diamond-Blackfan Anemia Registry. J Pediatr Hematol Oncol. 2001;23:39–44
  79. Vlachos A, Klein GW, Lipton JM. The Diamond Blackfan Anemia Registry: Tool for investigating the epidemiology and biology of Diamond-Blackfan anemia. J Pediatr Hematol Oncol. 2001;23:377–382
  80. Willig TN, Niemeyer CM, Leblanc T, Tiemann C, Robert A, Budde J, et al. Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients (DBA group of Societe d’Hematologie et d’Immunologie Pediatrique (SHIP), Gesellshaft fur Padiatrische Onkologie und Hamatologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPHI)). Pediatr Res. 1999;46:553–561
  81. Janov AJ, Leong T, Nathan DG, Guinan EC. Diamond-Blackfan anemia (Natural history and sequelae of treatment). Medicine (Baltimore). 1996;75:77–78
  82. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000;110:768–779
  83. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: An update of the GITMO/EBMT study on 100 patients (European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO)). Blood. 2000;95:1931–1934
  84. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–2054
  85. Fuhrer M, Burdach S, Ebell W, Gadner H, Haas R, Harbott J, et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): The SAA 94 experience (German/Austrian Pediatric Aplastic Anemia Working Group). Klin Padiatr. 1998;210:173–179
  86. Ohara A, Kojima S, Okamura J, Inada H, Kigasawa H, Hibi S, et al. Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia. Br J Haematol. 2002;116:151–154
  87. Maserati E, Minelli A, Menna G, Cecchini MP, Bernardo ME, Rossi G, et al. Familial myelodysplastic syndromes, monosomy 7/trisomy 8, and mutator effects. Cancer Genet Cytogenet. 2004;148:155–158
  88. Hasle H. Myelodysplastic and myeloproliferative disorders in children. Curr Opin Pediatr. 2007;19:1–8

PII: S0037-1963(07)00157-6

doi: 10.1053/j.seminhematol.2007.10.006

Seminars in Hematology
Volume 45, Issue 1 , Pages 60-70 , January 2008

Article Tools

* Image Usage & Resolution